StreetAlpha.app
Home › Stocks › IMTX

Immatics N.V. (IMTX)

Healthcare
$6.29
▲ +1.94%
LAST CLOSE · NOV 17

Immatics develops PRAME-targeted cancer treatments, including cell therapies and bispecific drugs, for patients with advanced cancers. It last closed at $6.29 on Nov 17, up 1.94% on the day.

AI Auto Pilots
Is IMTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−EUR 196.4M
−1390.9% vs a year ago
Free cash flow
−EUR 183.2M
Balance sheet
Cash & equivalents
EUR 345.9M
At Dec 31
Shareholder equity
EUR 484.1M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −EUR 93.3M−EUR 93.3MFY2021FY2022: EUR 27.7MEUR 27.7MFY2022FY2023: −EUR 94.6M−EUR 94.6MFY2023FY2024: EUR 15.2MEUR 15.2MFY2024FY2025: −EUR 196.4M−EUR 196.4MFY2025

From IMTX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 5). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated IMTX in the past 90 days, not enough for a consensus
Average 12-month target
$15.00
▲ 138.5% upside

Based on 1 analyst who set a price target on IMTX in the past 90 days. The average target is $15.00, with a high of $15.00 and a low of $15.00, compared with the last close of $6.29.

Low $15.00Avg $15.00High $15.00
Blue marker: last close $6.29
Highest target$15.00
Average target$15.00
Lowest target$15.00
Latest rating changes
StifelInitiated
Oct 14Buy$15
Chardan CapitalMaintained
May 19Buy$25
DateFirmActionRatingPrice target
Oct 14StifelInitiatedBuy$15
May 19Chardan CapitalMaintainedBuy$25
Loading…

Technical Analysis

IMTX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 9% below its 20 day and 20% below its 50 day average. It is 49% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot at $6.22, and the nearest resistance the Pivot R1 at $6.37.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 6.9%/day
Key levels
$12.4152 week high+97.3%
$9.39200 day average+49.3%
$8.49100 day average+35.0%
$7.5850 day average+20.5%
$6.89Swing high (Nov 12)+9.5%
$6.8720 day average+9.2%
$6.37Pivot R1+1.3%
$6.29Last close
$6.22Pivot−1.1%
$6.15Pivot S1−2.2%
$6.10Swing low (Nov 6)−3.0%
$6.0752 week low−3.5%
Indicators
RSI (14)36.16Weak, oversold below 30Neutral
MACD-0.37Below its signal lineBearish
Stochastic14.4Near the bottom of its rangeOversold
ADX (14)30.5Trending down
Williams %R-84.8Oversold below −80, overbought above −20Oversold
CCI (20)-102.1Oversold below −100, overbought above 100Oversold
Rate of change−11.1%Change over 10 sessionsBearish
ATR (14)$0.43Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMTX

What happened before

See how IMTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IMTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IMTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IMTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

IMTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲61 buying vs 35 selling
  • ▲Shares held by funds +11.3%
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding9184+8.3%
In funds' top 1000–
Held by funds–––
New / increased22 / 3912 / 25+64.9%
Reduced / sold out21 / 1434 / 13−25.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMTX is in one of them and how their past IMTX trades turned out.

IMTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMTX in an article yet. Here's the latest on the wider market.

About Immatics N.V.

Immatics is a biopharmaceutical company based in Tubingen, Germany, that develops cancer treatments aimed at PRAME, a protein found on the surface of many tumor cells. Its main products are T cell receptor therapies in two forms. Its cell therapies are made individually for each patient, while its bispecific drugs are made in advance and distributed through standard pharmaceutical supply channels. The treatments are intended for patients with advanced cancers, such as melanoma, and are given through specialized hospitals and medical centers.

Headquarters
Tubingen, Germany